Clinical studies with silymarin: fibrosis progression is the end point.
Schuppan
D
D
Hahn
E G
EG
D002756:Cholagogues and Choleretics / Q000627:therapeutic use*; D018450:Disease Progression; D004359:Drug Therapy, Combination; D005355:Fibrosis; D006801:Humans; D008105:Liver Cirrhosis, Biliary / Q000188:drug therapy* / Q000473:pathology; D020011:Protective Agents / Q000627:therapeutic use*; D019233:Retreatment; D012838:Silymarin / Q000627:therapeutic use*; D014580:Ursodeoxycholic Acid / Q000627:therapeutic use*
D002756:Cholagogues and Choleretics; D020011:Protective Agents; D012838:Silymarin; D014580:Ursodeoxycholic Acid